Furthermore, MEK inhibitors are clinically effective primarily in RAF mutant cancers, where preclinical studies have found that lower concentrations of these drugs are needed to inhibit MEK/ERK signaling (Corcoran et al., 2013). Here, MAP2K7 is linked to cancer.